TransCode TherapeuticsOffering
TransCode is a pre-clinical biopharmaceutical company focused on the development and commercialization of therapeutics to treat metastatic cancer.
TransCode is a pre-clinical biopharmaceutical company focused on the development and commercialization of therapeutics to treat metastatic cancer.
the SEC regulation only requires stockbrokers to have reasonable access ... on the specific ATS, plus the cost of filing with the States for secondary market ... Systems (ATS) Summarize Title IV Regulation A+ for me Reg A+ liquidity ...
environmentally friendly, sustainable and lower cost. Download Presentation KEY ... IN PERFORMANCE ECO-FRIENDLY AND SUSTAINABLE LOWER COST Superior in Performance ... transportation and handling costs. 2.5X the tensile strength of steel. ...
Offering Completed - Your Rare Opportunity to access Pre-IPO Stock in Impossible Foods
CubCrafters capital raise will be used to increase manufacturing capacity ... for a public stock offering of up to $50 million using the Regulation ... now launched a new Regulation CF campaign, offering the same preferred ...
Bringing Trust to the $120 billion Skincare Industry
raising capital lists its stock on an exchange or other trading forum. ... Commission to make a $50 million public stock offering under Regulation A+, ... Learn more at: https://cubcrafters.com/investors Regulation A of Title IV ...
leased equipment to businesses in need, for no up front capital ... treatment systems scaled down in size and cost, but not in capability. ... THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT ...
Invest in Remote-Controlled Drug Delivery
planned Reg A+ IPO Related Content: Reg A+ IPO with Manhattan Street Capital Post of taking your company public using Regulation A+ Timeline schedule ...